Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of MK3207 in the Treatment of Acute Migraine.

Next Previous
Trial Profile

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of MK3207 in the Treatment of Acute Migraine.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 3207 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck & Co; Merck Sharp & Dohme

Most Recent Events

  • 28 Apr 2012 Planned number of patients changed from 522 to 685 as reported by European Clinical Trials Database record.
  • 28 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database record.
  • 24 Feb 2009 Actual end date changed from 1 Jan 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top